Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Express Scripts
Baxter
Boehringer Ingelheim
Merck

Last Updated: February 1, 2023

Patent: 4,621,053


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 4,621,053
Title: Process for the production of human peptide hormones
Abstract:Human peptide hormones, such as insulin, growth hormone, prolactin, adrenocorticotropic hormone, placental lactogen, calcitonin, parathyroid hormone and thyroid stimulating hormone, are produced by implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing the human peptide hormone in a non-human warm-blooded animal. After a period of time, the resultant tumor is extracted and disaggregated and then cultured in vitro under conditions appropriate to accumulate the human peptide hormone. The human.times.human hybridoma lymphoblastoid cell line is preferably formed by fusing parent human cells inherently capable of producing the human peptide hormone with a human lymphoblastoid line, preferably of leukemic origin. This process permits a substantial increase in the amount of human peptide hormone which can be produced.
Inventor(s): Sugimoto; Kaname (Okayama, JP)
Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (Okayama, JP)
Application Number:06/584,017
Patent Claims:see list of patent claims

Details for Patent 4,621,053

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 10/28/1982 See Plans and Pricing 2000-07-30
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 12/29/2015 See Plans and Pricing 2000-07-30
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 08/06/1998 See Plans and Pricing 2000-07-30
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 03/31/1994 See Plans and Pricing 2000-07-30
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 05/25/2018 See Plans and Pricing 2000-07-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
McKinsey
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.